9 results about "Protective antigen" patented technology

The application discloses a multivalent biological toxin antigen vaccine based on double receptor binding domain (RBD) assembly and a preparation method and application thereof. The application provides a multivalent biological toxin molecular antigen vaccine, and an active ingredient of the vaccine is a fusion protein formed by connecting an Hc protective antigen of biological toxin 1 and an Hc protective antigen of biological toxin 2 through a connecting peptide; the biological toxin 1 and the biological toxin 2 are two different biological toxins; and the biological toxin is selected from the following: tetanus toxin or other types of botulinum toxin (including types A, B and H) except type E. The application proves that different serotypes of botulinum toxin and tetanus toxin receptor binding domain Hc antigens are fused and assembled into a double Hc fusion antigen molecule by using genetic engineering and biosynthesis technology, and the double Hc fusion antigen molecule can generate strong protection against multiple biological toxins as a single subunit vaccine. Therefore, the Hc fusion antigen molecule vaccine of the application can generate protection against multiple different serotypes of biological toxin pathogens, and can be used as a broad-spectrum multivalent vaccine for biological toxin prevention and preventive treatment.

The present application relates to a kind of mycobacterium tuberculosis protective antigen combination and its application, specifically, the antigen of the application is combination antigen, at least includes the following antigen: Ag85B, Rv2465c, Rv2029c, Rv3406;The application is the vaccine for resisting mycobacterium tuberculosis.

This invention belongs to the field of vaccine technology, specifically relating to a method for effectively activating the body's immune system against tuberculosis infection by identifying candidate antigen epitopes for mRNA vaccines. The method comprises the following steps: screening for population-specific tuberculosis protective antigens based on reverse prediction from a TCR immune repertoire; constructing an mRNA vaccine containing these population-specific tuberculosis protective antigens and identifying the optimal antigen; and evaluating the in vivo immunogenicity, immunogenicity, and immunoprotective effects of the mRNA vaccine. This technical solution combines population-specific common HLA allele profiles with existing tuberculosis-specific TCR databases to target and predict broad-spectrum protective antigens recognized by TCRs shared under the major HLA backgrounds in the population. LNP-mRNA vaccine technology has been established as an ideal platform for delivering these newly discovered advantageous antigens.

The present invention relates to a protective antigen combination of Mycobacterium tuberculosis and the use thereof. Specifically, the antigen is a combined antigen and contains at least the following antigens: Ag85B, Rv2465c, Rv2029c and Rv3406. The use is for the preparation of a vaccine against Mycobacterium tuberculosis.

The application discloses a fusion protein PP13138R and application thereof in tuberculosis prevention. Specifically disclosed is a fusion protein comprising HTL, CTL and B cell epitopes in series, PorB, PADRE and RS-09. The application screens 34 epitopes for Mycobacterium tuberculosis, which have good immunogenicity and antigenicity and no toxicity and no sensitization, and have the characteristics of high population coverage and the like. The auxiliary peptide PADRE is further added to improve the immunogenicity of the vaccine, and the PorB and RS-09 are added to endow the vaccine with a targeted delivery function. In-vitro experiments prove that the PP13138R can stimulate human peripheral blood mononuclear cells to produce an immune response, and is an advantage protective antigen. The PP13138R has the advantages of simple preparation method, low cost, high yield and higher safety as a vaccine. The application has great value for the prevention and treatment of active tuberculosis and latent tuberculosis infection.

This invention discloses a chimeric antiviral cross-protective antigen mRNA vaccine, its preparation method, and its application. The vaccine consists of lipid materials encapsulating either a first or second type of mRNA, forming nanolipid nanoparticles containing mRNA fragments. The first type of mRNA is obtained through in vitro transcription using a first DNA template, and the second type of mRNA is obtained through in vitro transcription using a second DNA template. The vaccine of this invention possesses the advantage of multi-antigen comprehensive immunity: each vaccine combines one EEV core surface antigen and one IMV core surface antigen. This chimeric strategy can simultaneously induce highly efficient and specific immunity against both types of viral infection particles, both limiting initial viral entry into cells and effectively clearing free viruses from the circulatory system. It not only stimulates strong humoral immunity but also induces specific cellular immune responses, thereby significantly enhancing the vaccine's broad-spectrum cross-protective efficacy against orthopox, vaccinia virus, and other orthopox viruses.

The application discloses a fusion protein HP13138PB and application thereof in tuberculosis prevention. Specifically disclosed is a fusion protein comprising HTL, CTL and B cell epitopes in series, HBD-3, PSM alpha 4 and PADRE. The application screens 34 epitopes for mycobacterium tuberculosis, which have good immunogenicity and antigenicity and no toxicity and sensitization, and have the characteristics of high population coverage and the like. The immunogenicity of the vaccine is improved by further adding antibacterial peptide HBD-3 and auxiliary peptide PADRE, and PSM alpha 4 is added to endow the vaccine with targeted delivery function. In-vitro experiments prove that HP13138PB can stimulate human peripheral blood mononuclear cells to produce an immune response, and is an advantage protective antigen. The HP13138PB as a vaccine has the advantages of simple preparation method, low cost, high yield and higher safety and the like. The application has great value for the prevention and treatment of active tuberculosis and latent tuberculosis infection.

This invention discloses the polypeptide fusion protein CP13138P and its application in tuberculosis prevention. Specifically, it discloses a fusion protein comprising tandem HTL, CTL, and B-cell epitopes, CTB, Pam2Cys, and PADRE. This invention screened 34 epitopes targeting Mycobacterium tuberculosis, which exhibit excellent immunogenicity and antigenicity, are non-toxic and non-sensitizing, and have high population coverage. In vitro experiments demonstrate that CP13138P can stimulate an immune response in human peripheral blood mononuclear cells (PBMCs), increasing IFN-γ in PBMCs. + The number of T lymphocytes is significantly increased, and they secrete significantly high levels of more than a dozen cytokines, including G-CSF, making them a dominant protective antigen. CP13138P, as a vaccine, has advantages such as simple preparation method, low cost, high yield, and enhanced safety. This invention has significant value for the prevention and treatment of active tuberculosis and latent tuberculosis infection.

The application discloses a gene modified non-toxic toxoid vaccine based on light chain-transmembrane region L-HN and receptor binding region Hc, and a preparation method and application thereof. The gene modified non-toxic novel toxoid vaccine molecule has two important protective antigen functional domains of a biological toxin, the N terminal of the vaccine molecule is the light chain-transmembrane region L-HN, and the C terminal is the receptor binding region Hc. The two protective antigen functional domains can be derived from the same biological toxin, can produce stronger protection than a single antigen, can produce strong complete protection at a low dose and a small number of immunization times, and can be used as a high-efficiency gene engineering toxoid vaccine to replace formaldehyde inactivated toxoid for biological toxin prevention. The two protective antigen functional domains can also be derived from different biological toxins, can protect against attacks of respective biological toxins, can produce protection against multiple different toxin biological agents, and can be used as a broad-spectrum multivalent vaccine for biological toxin prevention.